Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Taal, Walter, MD, Oosterkamp, Hendrika M, MD, Walenkamp, Annemiek M E, MD, Dubbink, Hendrikus J, PhD, Beerepoot, Laurens V, MD, Hanse, Monique C J, MD, Buter, Jan, MD, Honkoop, Aafke H, MD, Boerman, Dolf, MD, de Vos, Filip Y F, MD, Dinjens, Winand N M, PhD, Enting, Roelien H, MD, Taphoorn, Martin J B, MD, van den Berkmortel, Franchette W P J, MD, Jansen, Rob L H, MD, Brandsma, Dieta, MD, Bromberg, Jacoline E C, MD, van Heuvel, Irene, Vernhout, René M, MSc, van der Holt, Bronno, PhD, van den Bent, Martin J, Prof
Published in The lancet oncology (01.08.2014)
Published in The lancet oncology (01.08.2014)
Get full text
Journal Article